BioCryst Pharmaceuticals, Inc.
NASDAQ:BCRXBiotechnology
+$0.09 today
- Market cap
- $1.88B
- Beta
- 0.56
- P/E (TTM)
- -4.8
- EPS (TTM)
- -$1.89
Volume 2.95M
Average 4.85M
BCRX Sales of Investments
Cash received from selling or redeeming investments.
BioCryst Pharmaceuticals, Inc.NASDAQ: BCRX
Sales of Investments · Q2 FY2026 · quarter ended Jun 2026
Sales of investments dips below year-ago levels
Q2 FY2026 sales of investments of $25.7M fell 56.2% year over year, behind the +61.7% change in trailing-twelve-month sales of investments. Sequentially, it fell 88.4% from the prior quarter. Over 3 fiscal years it compounded at +29.8% a year.
Context
- Sales of investments amounted to 29.3% of revenue in FY2025, down 41.8 pp from a year earlier.
- Sales of investments increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from -56.2% toward the trailing-twelve-month pace of +61.7%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Sales of Investments history
USD · from the cash flow
- Latest · FY2025
- 256.65M USD
- Year-over-year change
- -19.9%
- 4-year CAGR
- +73.7%
| Period | Period end | Sales of Investments | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 256.65M | -19.9% |
| FY2024 | 2024-12-31 | 320.48M | -16.8% |
| FY2023 | 2023-12-31 | 385.08M | +228.0% |
| FY2022 | 2022-12-31 | 117.4M | +316.3% |
| FY2021 | 2021-12-31 | 28.2M | — |
Sales of Investments vs competitors
How BCRX compares with its peers on the latest reported figures
- Peers report in different currencies, so sales of investments is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +61.7% is the highest of 3, against a peer median of -26.5%.
- Sales of investments amounts to 39.2% of revenue for BCRX, versus a peer median of 1633.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $1.07B USD | -26.1% | +50.6% | 1633.7% | |
| LTM Jun 2026 | $368.93M USD | +61.7% | +29.8% | 39.2% | |
| LTM Mar 2026 | $366.77M USD | -26.9% | +72.4% | — | |
| LTM Sep 2026 | €0 EUR | — | — | — | |
| Peer median (excluding BCRX) | — | -26.5% | +61.5% | 1633.7% | |
Competitors are the stored peer set for BCRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (184.06M) | (247.12M) | (226.54M) | (88.88M) | 263.86M |
| Depreciation & Amortization | 777K | 1.44M | 1.66M | 1.25M | 1.39M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 34.64M | 44.7M | 55.62M | 65.41M | 85.07M |
| Change in Working Capital | 8.12M | (58.95M) | (32.4M) | (87.28M) | (56.9M) |
| Accounts Receivables | (20.82M) | (21.47M) | (6.1M) | (22.7M) | (36.81M) |
| Inventory | (8.77M) | (12.42M) | (1.45M) | (4.16M) | (1.64M) |
| Accounts Payables | 39.41M | (22.36M) | (16.81M) | (62.38M) | 57.8M |
| Other Working Capital | (1.7M) | (2.69M) | (8.05M) | 1.96M | (76.26M) |
| Other Non-Cash Items | (1.64M) | 98.07M | 106.53M | 57.48M | 36.46M |
| Operating Cash Flow | (142.16M) | (161.85M) | (95.14M) | (52.02M) | 329.88M |
| Capital Expenditures | (2.39M) | (1.35M) | (2.17M) | (1.12M) | (2.47M) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | (6.18M) |
| Purchases of Investments | (10.01M) | (244.28M) | (514.41M) | (266.76M) | (262.24M) |
| Sales of Investments | 28.2M | 117.4M | 385.08M | 320.48M | 256.65M |
| Other Investing Activities | 0 | 0 | 0 | 0 | 550K |
| Investing Cash Flow | 15.8M | (128.24M) | (131.5M) | 52.59M | (13.69M) |
| Debt Repayment | 293.87M | 73.07M | 58.38M | (1.7M) | (332.77M) |
| Common Stock Issued | 50.06M | 190K | 342K | 34K | 9.17M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 15.73M | 14.77M | (26.24M) | (4.09M) | (8.85M) |
| Financing Cash Flow | 359.67M | 88.03M | 32.49M | (5.76M) | (332.44M) |
| Effect of Forex Changes | 71K | 566K | 362K | (936K) | (87.07M) |
| Net Change in Cash | 233.39M | (201.5M) | (193.79M) | (6.12M) | (103.32M) |
| Free Cash Flow | (144.54M) | (163.2M) | (97.31M) | (53.14M) | 327.41M |
BioCryst Pharmaceuticals, Inc.
NASDAQ:BCRX
Intrinsic Alpha fair value
Locked
Current Price
$7.30
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.